Trial Profile
Phase 0 trial of oral AB 224050
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Sep 2009
Price :
$35
*
At a glance
- Drugs AB 224050 (Primary)
- Indications Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection
- Focus Pharmacokinetics
- Sponsors Active Biotech; Chelsea Therapeutics
- 05 Sep 2009 New trial record.